ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Articles

Japan becomes a new frontier

Teva Pharmaceutical Industries is boosting production capacity for generics to be sold in Japan.

TOKYO -- Leading generic-drug makers are ready to tap into the Japanese market. The government in Tokyo recently moved to promote more use of generics in the country. It aims to raise the share of generic drug prescriptions to 80% between fiscal 2018 and 2020. The policy may change the power dynamics among foreign and Japanese drugmakers.

     South African generics maker Aspen Pharmacare Holdings on Wednesday launched operations in Japan. Aspen Japan plans to sell five generics in the country, including anti-cancer drugs. Generic drugs are copies of original brand-name medicines for which the patents have expired. Aspen will obtain permission to sell in Japan from U.K.-based GlaxoSmithKline and U.S.-based Merck, the original drugmakers. Aspen targets sales of around 6 billion yen ($48.2 million) in the first year.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more